Liposomal delivery systems for anti-cancer analogues of vitamin E

Koudelka, Štěpán; Knotigová, Pavlína Turánek; Mašek, Josef; Procházka, Lubomír; Lukac, R; Miller, Andrew D.; Neužil, Jiřı́; Tuřánek, Jaroslav

doi:10.1016/j.jconrel.2015.04.003

Cited by 60 publications

(46 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 In addition, the intravenous or intraperitoneal administration of α-TOS in an organic phase or oil emulsion can cause important side effects, such as the formation of aggregates as a result of drug mixing with blood plasma, inflammation and embolization processes. 20 In recent years, the drug-loaded polymeric nanoparticles (NPs) offer bright promise for cancer therapy. [21][22][23][24] To potentially maximize therapeutic activity while minimizing negative side effects of 2-DG and α-TOS, an amphiphilic nanocarrier targeting folate receptor (FR) was designed and used in our study to deliver both chemoagents.…”

mentioning

confidence: 99%

Co-delivery nanocarriers targeting folate receptor and encapsulating 2-deoxyglucose and α-tocopheryl succinate enhance anti-tumor effect in vivo

Li¹,

Li²,

Liu³

et al. 2017

IJN

View full text Add to dashboard Cite

A combination administration of chemical agents was highlighted to treat tumors. Recently, tumor cell has been found to be different from normal cell in metabolic manner. Most of cancer cells prefer aerobic glycolysis to mitochondrial oxidative phosphorylation (OXPHOS) to satisfy energy and biomass synthesis requirement to survive, grow and proliferate, which provides novel and potential therapeutic targets for chemotherapy. Here, 2-deoxy- d -glucose (2-DG), a potent inhibitor of glucose metabolism, was used to inhibit glycolysis of tumor cells; α-tocopheryl succinate (α-TOS), a water-insoluble vitamin E derivative, was chosen to suppress OXPHOS. Our data demonstrated that the combination treatment of 2-DG and α-TOS could significantly promote the anti-tumor efficiency in vitro compared with administration of the single drug. In order to maximize therapeutic activity and minimize negative side effects, a co-delivery nanocarrier targeting folate receptor (FR) was developed to encapsulate 2-DG and α-TOS simultaneously based on our previous work. Transmission electron microscope, dynamic light scattering method and UV-visible spectrophotometers were used to investigate morphology, size distribution and loading efficiency of the α-TOS-2-DG-loaded and FR-targeted nanoparticles (TDF NPs). The TDF NPs were found to possess a layer-by-layer shape, and the dynamic size was <100 nm. The final encapsulation efficiencies of α-TOS and 2-DG in TDF NPs were 94.3%±1.3% and 61.7%±7.7% with respect to drug-loading capacities of 8.9%±0.8% and 13.2%±2.6%, respectively. Almost no α-TOS release was found within 80 h, and release of 2-DG was sustained and slow within 72 h. The results of FR binding assay and fluorescence biodistribution revealed that TDF NPs could target FR highly expressed on tumor cell in vitro and in vivo. Further, in vivo anti-tumor experiments showed that TDF NPs had an improved biological function with less toxicity. Thus, our work indicates that the co-delivery TDF NPs have a great potential in tumor therapy.

show abstract

mentioning

confidence: 99%

Co-delivery nanocarriers targeting folate receptor and encapsulating 2-deoxyglucose and α-tocopheryl succinate enhance anti-tumor effect in vivo

Li¹,

Li²,

Liu³

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…[35][36][37] Recently, several formulations of liposome-based DDSs have been approved by Food and Drug Administration and European Medicines Agency for the treatment of cancer. 38 Thus, in this study, DPPC, DSPE-PEG (common phospholipid material), and DOX (a water-soluble antitumor drug) were used to build a DOX-loaded liposome via film dispersion method. To obtain the photo-responsive ability of the liposome-based DDS, an efficient PS HMME (water-insoluble) was inserted into the lipid layer of the DOX-loaded liposome.…”

Section: Discussionmentioning

confidence: 99%

A nanoliposome-based photoactivable drug delivery system for enhanced cancer therapy and overcoming treatment resistance

Shi¹,

Su²,

Liu³

et al. 2017

IJN

View full text Add to dashboard Cite

Recently, stimuli-responsive drug delivery systems (DDSs) with high spatial/temporal resolution bring many benefits to cancer treatment. However, cancer cells always develop ways to resist and evade treatment, ultimately limit the treatment efficacy of the DDSs. Here, we introduce photo-activated nanoliposomes (PNLs) that impart light-induced cytotoxicity and reversal of drug resistance in synchrony with a photoinitiated and rapid release of antitumor drug. The PNLs consist of a nanoliposome doped with a photosensitizer (hematoporphyrin monomethyl ether [HMME]) in the lipid bilayer and an antitumor drug doxorubicin (DOX) encapsulated inside. PNLs have several distinctive capabilities: 1) carrying high loadings of DOX and HMME and releasing the payloads in a photo-cleavage manner with high spatial/temporal resolution at the site of actions via photocatalysis; 2) reducing drug efflux in MCF-7/multidrug resistance cells via decreasing the level of P-glycoprotein induced by photodynamic therapy (PDT); 3) accumulating in tumor site taking advantage of the enhanced permeability and retention effect; and 4) combining effective chemotherapy and PDT to exert much enhanced anticancer effect and achieving significant tumor regression in a drug-resistant tumor model with little side effects.

show abstract

“…Antioxidants, probiotics, polyunsaturated fatty acids, and proteins are common bioactives that can be added to food to improve nutritional value, to prevent diseases and to improve overall health [212]. Nanodelivery of these components may improve their stability [213,214], solubility [215,216], functionality [217,218], cellular uptake [219][220][221], and bioavailability [222][223][224] and may also provide controlled release [225][226][227] for better efficacy of the bioactive.…”

Section: Food Applicationsmentioning

confidence: 99%

Novel nanoparticle materials for drug/food delivery-polysaccharides

Chen

Liu

Wong

2016

Physical Sciences Reviews

View full text Add to dashboard Cite

Liposomal delivery systems for anti-cancer analogues of vitamin E

Cited by 60 publications

References 98 publications

Co-delivery nanocarriers targeting folate receptor and encapsulating 2-deoxyglucose and α-tocopheryl succinate enhance anti-tumor effect in vivo

Co-delivery nanocarriers targeting folate receptor and encapsulating 2-deoxyglucose and α-tocopheryl succinate enhance anti-tumor effect in vivo

A nanoliposome-based photoactivable drug delivery system for enhanced cancer therapy and overcoming treatment resistance

Novel nanoparticle materials for drug/food delivery-polysaccharides

Contact Info

Product

Resources

About

Liposomal delivery systems for anti-cancer analogues of vitamin E

Cited by 60 publications

References 98 publications

Co-delivery nanocarriers targeting folate receptor and encapsulating 2-deoxyglucose and &alpha;-tocopheryl succinate enhance anti-tumor effect in vivo

Co-delivery nanocarriers targeting folate receptor and encapsulating 2-deoxyglucose and &alpha;-tocopheryl succinate enhance anti-tumor effect in vivo

A nanoliposome-based photoactivable drug delivery system for enhanced cancer therapy and overcoming treatment resistance

Novel nanoparticle materials for drug/food delivery-polysaccharides

Contact Info

Product

Resources

About

Co-delivery nanocarriers targeting folate receptor and encapsulating 2-deoxyglucose and α-tocopheryl succinate enhance anti-tumor effect in vivo

Co-delivery nanocarriers targeting folate receptor and encapsulating 2-deoxyglucose and α-tocopheryl succinate enhance anti-tumor effect in vivo